- Get in Touch with Us
Last Updated: Apr 26, 2025 | Study Period: 2024-2030
An antibiotic is cefuroxime. It functions by halting the development of the bacterial protective coating, which is necessary for bacteria to survive in the human body.
A beta-lactamase inhibitor, clavulanic acid prevents the action of bacterially generated enzymes that inactivate Cefuroxime combined with CLAVULANIC ACID Belonging to the class of drugs known as antibiotics that are used to treat a variety of bacterial diseases, including sinusitis, gonorrhoeic, Lyme disease, septicemia, pharyngitis/tonsillitis, otitis media, and ear infections.
For the management and treatment of bacterial infections, notably those caused by beta-lactamase-producing bacteria, clavulanic acid is a drug that can be used with amoxicillin. It belongs to the group of drugs called beta-lactamase inhibitors.
The Global cefuroxime clavulanic acid market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The present invention relates to pharmaceutical formulations including cefuroxime acetyl and clavulanic acid for use in treating and preventing infections caused by gramme positive and gramme negative bacteria in the upper respiratory tract, such as otitis media, sinusitis, tonsillitis, and pharyngitis;
Lower respiratory tract infections, such as pyelonephritis, cystitis, and urethritis; and skin and soft tissue infections, such as furan To prevent bacterial resistance and give even greater antibacterial resistance, tablet formulations are also being developed that combine a beta-lactam group cephalosporin antibiotic, like cefuroxime acetyl, and a beta-lactam inhibitor, like clavulanic acid.
The solubility and stability issues with cefuroxime acetyl formulations, however, are more pronounced in tablet formulations containing cefuroxime acetyl and clavulanic acid in the prior art because clavulanic acid has a significant propensity for moisture absorption because of its hygroscopic nature.
The current invention relates to formulations that contain cefuroxime acetyl and clavulanic acid and are created in film-coated tablet form. These formulations are distinguished by the fact that they contain at least one cellulose-based diluent and that the weight ratio of cefuroxime acetyl to diluent is between 1:5 and 5:1.
In another aspect, the present invention relates to formulations made into film-coated tablets that contain clavulanic acid and cefuroxime acetyl. It is distinguished by having at least one cellulose-based diluent and a ratio of cefuroxime acetyl to diluent that is preferably between 1:2 and 4:1 by weight.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.